La Jolla Pharmaceutical Company (LJPC):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:La Jolla Pharmaceutical Company (LJPC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10073
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:43
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
La Jolla Pharmaceutical Company (La Jolla) is a biopharmaceutical company that discovers, develops and commercializes pharmaceutical products for life threatening diseases. The company’s major product includes Giapreza, an injection for intravenous infusion indicated to increase blood pressure in adults with septic or other distributive shock. Its clinical-stage investigational product includes LJPC-401, a formulation of synthetic human hepcidin intended for the treatment of iron overload, such as hereditary hemochromatosis, sickle cell disease, beta thalassemia and myelodysplastic syndrome. The company distributes its products through a network of specialty distributors to hospitals across the US. La Jolla is headquartered in San Diego, California, the US.

La Jolla Pharmaceutical Company (LJPC) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
La Jolla Pharmaceutical Company, Medical Devices Deals, 2012 to YTD 2018 10
La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
La Jolla Pharma to Acquire Rights to Gentamicin Derivatives from IURTC 13
La Jolla Pharma Acquires GCS-100 From Solana Therapeutics 14
Licensing Agreements 15
La Jolla Pharma Enters into Licensing Agreement with Vanderbilt University 15
IURTC Enters into Licensing Agreement with La Jolla Pharma 16
IURTC and University of Alabama at Birmingham Enter into Licensing Agreement with La Jolla Pharma 17
La Jolla Pharma Enters into Licensing Agreement with George Washington University 18
La Jolla Pharma Enters Into Option For Licensing Agreement With George Washington University 19
Equity Offering 20
La Jolla Pharma Files Registration Statement for USD150 Million in Public Offering 20
La Jolla Pharmaceutical Raises USD125 Million in Underwritten Public Offering of Shares 21
La Jolla Pharma Prices Public Offering of Shares for USD100 Million 23
La Jolla Pharma Raises USD111.4 Million in Public Offering of Shares 24
La Jolla Pharma Raises USD56.6 Million in Public Offering of Shares 26
La Jolla Pharma Completes Private Placement Of Shares For US$6.7 Million 28
La Jolla Pharma Completes Private Placement Of Preferred Stock For US$3.3 Million 29
La Jolla Pharmaceutical Company – Key Competitors 30
La Jolla Pharmaceutical Company – Key Employees 31
La Jolla Pharmaceutical Company – Locations And Subsidiaries 32
Head Office 32
Other Locations & Subsidiaries 32
Recent Developments 33
Financial Announcements 33
Oct 24, 2018: La Jolla Pharmaceutical Company Reports Financial Results for the Three and Nine Months Ended September 30, 2018 33
Aug 08, 2018: La Jolla Pharmaceutical company announces financial results for the three and six months ended June 30, 2018 and recent corporate progress 34
May 10, 2018: La Jolla Pharmaceutical Company Announces Financial Results for the Three Months Ended March 31, 2018 and Recent Corporate Progress 35
Feb 22, 2018: La Jolla Pharmaceutical Company Announces Financial Results for the Three and Twelve Months Ended December 31, 2017 and Recent Corporate Progress 37
Oct 26, 2017: La Jolla Pharmaceutical Company Announces Financial Results for the Three and Nine Months Ended September 30, 2017 and Recent Corporate Progress 38
Jul 27, 2017: La Jolla Pharmaceutical Company Announces Financial Results for the Three and Six Months Ended June 30, 2017 and Recent Corporate Progress 39
Apr 27, 2017: La Jolla Pharmaceutical Company Announces Financial Results for the Three Months Ended March 31, 2017 and Recent Corporate Progress 40
Feb 23, 2017: La Jolla Pharmaceutical Company Announces Fourth Quarter and Full Year 2016 Financial Results and Corporate Progress 41
Product News 42
09/13/2017: Researchers Develop New Strategy to Target KRAS Mutant Cancer 42
Appendix 43
Methodology 43
About GlobalData 43
Contact Us 43
Disclaimer 43

List of Tables
La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Key Facts, 2017 2
La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
La Jolla Pharmaceutical Company, Deals By Therapy Area, 2012 to YTD 2018 9
La Jolla Pharmaceutical Company, Medical Devices Deals, 2012 to YTD 2018 10
La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
La Jolla Pharma to Acquire Rights to Gentamicin Derivatives from IURTC 13
La Jolla Pharma Acquires GCS-100 From Solana Therapeutics 14
La Jolla Pharma Enters into Licensing Agreement with Vanderbilt University 15
IURTC Enters into Licensing Agreement with La Jolla Pharma 16
IURTC and University of Alabama at Birmingham Enter into Licensing Agreement with La Jolla Pharma 17
La Jolla Pharma Enters into Licensing Agreement with George Washington University 18
La Jolla Pharma Enters Into Option For Licensing Agreement With George Washington University 19
La Jolla Pharma Files Registration Statement for USD150 Million in Public Offering 20
La Jolla Pharmaceutical Raises USD125 Million in Underwritten Public Offering of Shares 21
La Jolla Pharma Prices Public Offering of Shares for USD100 Million 23
La Jolla Pharma Raises USD111.4 Million in Public Offering of Shares 24
La Jolla Pharma Raises USD56.6 Million in Public Offering of Shares 26
La Jolla Pharma Completes Private Placement Of Shares For US$6.7 Million 28
La Jolla Pharma Completes Private Placement Of Preferred Stock For US$3.3 Million 29
La Jolla Pharmaceutical Company, Key Competitors 30
La Jolla Pharmaceutical Company, Key Employees 31
La Jolla Pharmaceutical Company, Subsidiaries 32

List of Figures
La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
La Jolla Pharmaceutical Company, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[La Jolla Pharmaceutical Company (LJPC):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Salvatore Ferragamo SpA (SFER):企業の財務・戦略的SWOT分析
    Salvatore Ferragamo SpA (SFER) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Alkermes Plc (ALKS):企業の財務・戦略的SWOT分析
    Alkermes Plc (ALKS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • PLx Pharma Inc (PLXP)-製薬・医療分野:企業M&A・提携分析
    Summary PLx Pharma Inc (PLx Pharma) is a drug development company that develops patent-protected delivery systems. The company’s products include PLxGuard delivery system, PLxGuard pipeline products, PL2200 aspirin and PL1100 and PL1200 ibuprofen products. Its PLxGuard delivery system are used in en …
  • 21st Century Oncology Inc:企業の戦略的SWOT分析
    21st Century Oncology Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Danone SA:企業の戦略・SWOT・財務情報
    Danone SA - Strategy, SWOT and Corporate Finance Report Summary Danone SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • AFC Energy plc (AFC):企業の財務・戦略的SWOT分析
    Summary AFC Energy Plc (AFC Energy) is a developer of alkaline fuel cells. The company's projects include Power-Up and Alkammonia. AFC Energy power generation technology is used in the industrial markets and produces heat, water, and electricity. The company provides its electricity for industrial a …
  • Rio Grande Electric Cooperative, Inc.:企業の戦略的SWOT分析
    Rio Grande Electric Cooperative, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and maj …
  • AmpliPhi Biosciences Corp (APHB):製薬・医療:M&Aディール及び事業提携情報
    Summary AmpliPhi Biosciences Corp (AmpliPhi) is a biotechnology company which focuses on development and commercialization of bacteriophage-based antibacterial therapeutics. The company by utilizing its proprietary bacteriophage technology developed a pipeline of products for the treatment of variou …
  • Edge Therapeutics Inc (EDGE)-製薬・医療分野:企業M&A・提携分析
    Summary Edge Therapeutics Inc (Edge Therapeutics) is a clinical-stage biotechnology company that discovers, develops and commercializes a range of hospital-based therapies. The company offers hospital based therapies capable of transforming treatment paradigms in the management of life-threatening, …
  • MetLife, Inc.:企業の戦略・SWOT・財務情報
    MetLife, Inc. - Strategy, SWOT and Corporate Finance Report Summary MetLife, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Sega Sammy Holdings Inc (6460):企業の財務・戦略的SWOT分析
    Sega Sammy Holdings Inc (6460) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • BRF SA:企業のM&A・事業提携・投資動向
    BRF SA - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's BRF SA Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital rais …
  • Avara Pharmaceutical Services Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Avara Pharmaceutical Services Inc (Avara) is a contract development and manufacturing organization that provides primary formulation and manufacturing, secondary manufacturing and packaging of small molecules. It offers wide range of services such as manufacturing of active pharmaceutical in …
  • Orezone Gold Corporation:企業の戦略・SWOT・財務情報
    Orezone Gold Corporation - Strategy, SWOT and Corporate Finance Report Summary Orezone Gold Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Dai-ichi Life Holdings, Inc.:企業の戦略・SWOT・財務情報
    Dai-ichi Life Holdings, Inc. - Strategy, SWOT and Corporate Finance Report Summary Dai-ichi Life Holdings, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Huiyin Household App. (Hold.) Co., Ltd.:戦略・SWOT・企業財務分析
    Huiyin Household App. (Hold.) Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Huiyin Household App. (Hold.) Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT a …
  • Aushon BioSystems Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Aushon BioSystems Inc (Aushon) is a medical device provider that provides biomarker measurement and analysis products. The company offers biomarker therapeutic areas in microarray printing technology. It provides products such as ciraplex assay, cirascan imaging and cirasoft analysis and cir …
  • Sun Pharmaceutical Industries Ltd:企業のM&A・事業提携・投資動向
    Sun Pharmaceutical Industries Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Sun Pharmaceutical Industries Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mer …
  • Lithia Motors, Inc.:企業のM&A・事業提携・投資動向
    Lithia Motors, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Lithia Motors, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), …
  • Laboratoire Aguettant SA:製薬・医療:M&Aディール及び事業提携情報
    Summary Laboratoire Aguettant SA (Aguettant) is a pharmaceutical company that that focuses on the development, manufacturing and commercialisation of injectable hospital medicines. The company offers sterile injectable medicines in various dosages and pharmaceutical forms. It provides its products f …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆